HIV antibody safety study for newborns at risk
Treatments studied
Part of Infections clinical trials.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The infant's birth parent has HIV infection and is willing to provide consent.
- The infant was born at 36 weeks or later, weighing at least 4.4 pounds (2 kg).
- The infant is less than 72 hours old at the start and will receive the study product within 72 hours of birth.
- The infant has normal blood counts (hemoglobin, platelets, white blood cells) and liver function.
- The infant is generally healthy and at higher risk of getting HIV (for example, if the birthing parent had high virus levels or wasn't on HIV medication).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This study tests whether giving a special antibody treatment to babies living with HIV, shortly after birth, can help their immune system fight the virus better. It aims to improve their long-term health.
This trial tests an experimental vaccine for babies who were exposed to HIV while in the womb but are not infected. Mothers must be living with HIV, on treatment, and deliver by C-section at the study hospital in Soweto.
This trial tests a new antibody medication given as a shot to babies with HIV. It aims to help control the virus and may be an option for infants who are newly diagnosed or starting treatment.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.